140 related articles for article (PubMed ID: 25505255)
1. Proteinuria with first-line therapy of metastatic renal cell cancer.
Land JD; Chen AH; Atkinson BJ; Cauley DH; Tannir NM
J Oncol Pharm Pract; 2016 Apr; 22(2):235-41. PubMed ID: 25505255
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study.
Thiery-Vuillemin A; Theodore C; Jacobasch L; Schmitz J; Papandreou C; Guillot A; Emmanouilides C; Slimane K; Kelkouli N; Kim S; Nguyen Tan Hon T
Clin Genitourin Cancer; 2015 Jun; 13(3):231-8. PubMed ID: 25456838
[TBL] [Abstract][Full Text] [Related]
3. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.
Hainsworth JD; Rubin MS; Arrowsmith ER; Khatcheressian J; Crane EJ; Franco LA
Clin Genitourin Cancer; 2013 Sep; 11(3):270-5. PubMed ID: 23665131
[TBL] [Abstract][Full Text] [Related]
4. First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting.
Vogelzang NJ; Hackshaw MD; Hutson TE; Bhowmik D; Yap M; Rembert D; Jonasch E
Clin Genitourin Cancer; 2015 Jun; 13(3):210-7. PubMed ID: 25498215
[TBL] [Abstract][Full Text] [Related]
5. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
Bellmunt J; Pons F; Foreshew A; Fay AP; Powles T; Porta C; Bracarda S; Lampron ME; Cerbone L; Sternberg CN; Hutson TE; Choueiri TK
Clin Genitourin Cancer; 2014 Aug; 12(4):262-9. PubMed ID: 24795159
[TBL] [Abstract][Full Text] [Related]
6. Pazopanib for the treatment of metastatic renal cell carcinoma.
Pick AM; Nystrom KK
Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
[TBL] [Abstract][Full Text] [Related]
7. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Kaymakcalan MD; Xie W; Albiges L; North SA; Kollmannsberger CK; Smoragiewicz M; Kroeger N; Wells JC; Rha SY; Lee JL; McKay RR; Fay AP; De Velasco G; Heng DY; Choueiri TK
Cancer; 2016 Feb; 122(3):411-9. PubMed ID: 26540173
[TBL] [Abstract][Full Text] [Related]
8. Pazopanib for the treatment of renal cancer.
Al-Marrawi MY; Rini B
Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
[TBL] [Abstract][Full Text] [Related]
9. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
[TBL] [Abstract][Full Text] [Related]
10. Signaling inhibitors in metastatic renal cell carcinoma.
Escudier B
Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
[TBL] [Abstract][Full Text] [Related]
11. An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer.
Powles T; Sarwar N; Jones R; Wilson P; Boleti E; Protheroe A; Crabb SJ; Shamash J; Stockdale A; Rashid S; Nathan P; Chowdury S
Eur J Cancer; 2012 Nov; 48(17):3171-6. PubMed ID: 22766517
[TBL] [Abstract][Full Text] [Related]
12. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma.
Tomita Y; Uemura H; Fujimoto H; Kanayama HO; Shinohara N; Nakazawa H; Imai K; Umeyama Y; Ozono S; Naito S; Akaza H;
Eur J Cancer; 2011 Nov; 47(17):2592-602. PubMed ID: 21889330
[TBL] [Abstract][Full Text] [Related]
13. Folic Acid Reduces Mucositis in Metastatic Renal Cell Carcinoma Patients: A Retrospective Study.
Fristrup N; Donskov F
Clin Genitourin Cancer; 2019 Aug; 17(4):254-259. PubMed ID: 31101577
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.
Hainsworth JD; Spigel DR; Burris HA; Waterhouse D; Clark BL; Whorf R
J Clin Oncol; 2010 May; 28(13):2131-6. PubMed ID: 20368560
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Proteinuria Using Urine Protein : Creatine Ratio in Treatment with Molecular Targeted Agents for Advanced Renal Cell Carcinoma.
Nakamura K; Tanaka T; Masumori N; Miyamoto A; Hirano T
Biol Pharm Bull; 2020; 43(10):1506-1510. PubMed ID: 32999160
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
Xie M; He CS; Huang JK; Lin QZ
Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
[TBL] [Abstract][Full Text] [Related]
17. Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospective Chart Reviews.
Pal SK; Signorovitch JE; Reichmann WM; Li N; Koo V; Liu Z; Perez JR; Vogelzang NJ
Clin Genitourin Cancer; 2016 Apr; 14(2):160-7.e3. PubMed ID: 26707954
[TBL] [Abstract][Full Text] [Related]
18. Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data.
Sorich MJ; Rowland A; Kichenadasse G; Woodman RJ; Mangoni AA
Br J Cancer; 2016 Jun; 114(12):1313-7. PubMed ID: 27228299
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapies for renal cell carcinoma: review of adverse event management strategies.
Eisen T; Sternberg CN; Robert C; Mulders P; Pyle L; Zbinden S; Izzedine H; Escudier B
J Natl Cancer Inst; 2012 Jan; 104(2):93-113. PubMed ID: 22235142
[TBL] [Abstract][Full Text] [Related]
20. Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials.
Bono P; Oudard S; Bodrogi I; Hutson TE; Escudier B; Machiels JP; Thompson JA; Figlin RA; Ravaud A; Basaran M; Porta C; Bracarda S; Brechenmacher T; Lin C; Voi M; Grunwald V; Motzer RJ
Clin Genitourin Cancer; 2016 Oct; 14(5):406-414. PubMed ID: 27287020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
